Chlorpromazine affects autophagy in association with altered Rag GTPase-mTORC1-TFEB signaling

Front Cell Dev Biol. 2023 Sep 8:11:1266198. doi: 10.3389/fcell.2023.1266198. eCollection 2023.

Abstract

Autophagy is a critical protein and organelle quality control system, which regulates cellular homeostasis and survival. Growing pieces of evidence suggest that autophagic dysfunction is strongly associated with many human diseases, including neurological diseases and cancer. Among various autophagic regulators, microphthalmia (MiT)/TFE transcription factors, including transcription factor EB (TFEB), have been shown to act as the master regulators of autophagosome and lysosome biogenesis in both physiological and pathological conditions. According to the previous studies, chlorpromazine (CPZ), an FDA-approved antipsychotic drug, affects autophagy in diverse cell lines, but the underlying mechanism remains elusive. In our present study, we find that CPZ treatment induces TFEB nuclear translocation through Rag GTPases, the upstream regulators of mechanistic target of rapamycin complex 1 (mTORC1) signaling. Meanwhile, CPZ treatment also blocks autophagosome-lysosome fusion. Notably, we find a significant accumulation of immature autophagosome vesicles in CPZ-treated cells, which may impede cellular homeostasis due to the dysfunction of the autophagy-lysosome pathway. Interestingly and importantly, our data suggest that the expression of the active form of Rag GTPase heterodimers helps in reducing the accumulation of autophagosomes in CPZ-treated cells, further suggesting a major contribution of the Rag GTPase-mTORC1-TFEB signaling axis in CPZ-induced autophagic impairment.

Keywords: CPZ; Rag GTPases; TFEB; autophagy; mTORC1.

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Nos 82022022 and 82071274), the Project Funded by the Jiangsu Key Laboratory of Neuropsychiatric Diseases (BM2013003), the Project Funded by the Priority Academic Program Development of the Jiangsu Higher Education Institutes (PAPD), the Key Project of the Natural Science Foundation of Jiangsu Provincial Higher Education Institutions (21KJA180003), and the Postgraduate Research & Practice Innovation Program of Jiangsu Province.